Inside MedSpa — Daily Brief, 2026-08-09
The few things that actually moved in your field — distilled. The headlines are free. The so-what is for subscribers.
1Evolus Q2 profitability and guidance raise signal market share pressure on AbbVie
What happenedEvolus reported Q2 2026 revenue of $84.1M (21% YoY growth), third consecutive quarter of positive adjusted EBITDA, and raised full-year guidance. The company is aggressively marketing Jeuveau through its Evolus Rewards loyalty program to medspas.
2FDA accepts Botox Cosmetic supplemental application for masseter muscle prominence
What happenedThe FDA accepted AbbVie's supplemental biologics license application (sBLA) for Botox Cosmetic in the masseter muscle for jaw contouring. This is a new indication beyond the existing cosmetic approvals.
3InMode Q2 beats revenue estimates; energy-device demand remains steady
What happenedInMode reported Q2 2026 revenue of $95.6M, beating FactSet estimates of $93.1M, with EPS beat of $0.02. U.S. demand for RF microneedling and other energy modalities remained solid.
4Evolus Rewards program terms changed; review your rebate structure immediately
What happenedThe Evolus Rewards program page was updated with new terms, indicating a shift in manufacturer loyalty and rebate structure. No formal announcement was made.
This is one morning. Get it every morning.
The full brief — what each item means for your business and exactly what to do about it — lands in your inbox twice a week. $20 a month. Never miss the developments and rule changes that matter.
Get the brief — $20/mo